Liposomal daunorubicin and cytarabine

Phase 2Small molecule

Liposomal daunorubicin and cytarabine is one of 16 small molecule programs targeting Induction Chemotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Induction ChemotherapyRecruiting

Induction ChemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Induction Chemotherapy

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

6 2

Idamycin

Pfizer

Phase 3

3 3

Venclexta

AbbVie

Phase 3

2 4

Xospata

Astellas

Phase 3

1 5

Induction Phase1

Genmab

Phase 3

3 6

Taxotere

AAvyxa

Phase 2

6 7

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Phase 3

2 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 2

3 9

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

2 10

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Induction Chemotherapy

NCT04801797

Clinical

Trials by Indication[1]

Induction Chemotherapy1 trial

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Recruiting·MMassachusetts General Hospital·Phase 2·NCT04801797·172 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liposomal daunorubicin and cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal daunorubicin and cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal daunorubicin and cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

Liposomal daunorubicin and cytarabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Induction Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News